Nanjing Leads Biolabs Sets Up Nomination Committee to Tighten Governance and Board Selection

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an update.

Nanjing Leads Biolabs Co., Ltd. has established a Nomination Committee under its board of directors to strengthen its corporate governance structure in line with PRC company law, Hong Kong Listing Rules and the Corporate Governance Code. The newly adopted terms of reference define the committee’s composition, eligibility requirements, tenure and operating procedures, tasking it with setting selection criteria, procedures and recommendations for director and senior management appointments while mandating a majority of independent non-executive directors and at least one director of a different gender, signalling a more formalised, transparent and diversity-aware approach to board and executive appointments that should enhance oversight and protection of shareholder interests.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a PRC-based company listed in Hong Kong that operates under the Company Law of the PRC and the Listing Rules of The Stock Exchange of Hong Kong Limited, with a governance framework aligned to the Corporate Governance Code and its Articles of Association for H share issuers.

Average Trading Volume: 594,245

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.63B

For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.